Dr. Flinn Discusses the Efficacy of IPI-145 in CLL

Ian W. Flinn, MD, PhD
Published: Monday, Dec 09, 2013



Ian W. Flinn, MD, PhD, from the Sarah Cannon Research Institute, discusses the preliminary efficacy of IPI-145 in patients with chronic lymphocyic leukemia (CLL).

IPI-145 is a potent oral inhibitor PI3K-delta and -gamma that was examined in a phase I trial that enrolled 44 patients with relapsed or refractory CLL. Overall, there was a 47% overall response rate, as evaluated by modified IWCLL criteria, in a heavily pretreated population of patients with CLL, Flinn notes. Additionally, there was a 50% response rate even in patients with 17p deletions or TP53 mutation.

When considering the mild toxicity profile along with the efficacy, IPI-145 represents a very promising new treatment option, Flinn notes. As a result, IPI-145 will be further examined in a phase III trial in comparison to ofatumumab.

<<< View more from the 2013 ASH Annual Meeting



Ian W. Flinn, MD, PhD, from the Sarah Cannon Research Institute, discusses the preliminary efficacy of IPI-145 in patients with chronic lymphocyic leukemia (CLL).

IPI-145 is a potent oral inhibitor PI3K-delta and -gamma that was examined in a phase I trial that enrolled 44 patients with relapsed or refractory CLL. Overall, there was a 47% overall response rate, as evaluated by modified IWCLL criteria, in a heavily pretreated population of patients with CLL, Flinn notes. Additionally, there was a 50% response rate even in patients with 17p deletions or TP53 mutation.

When considering the mild toxicity profile along with the efficacy, IPI-145 represents a very promising new treatment option, Flinn notes. As a result, IPI-145 will be further examined in a phase III trial in comparison to ofatumumab.

<<< View more from the 2013 ASH Annual Meeting




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x